From dendritic cells to tumour vaccines

Lancet

Volumn 347, Issue 9003, 1996, Pages 705-706

  Hamblin, T J ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ANTIGEN PRESENTATION; CANCER REGRESSION; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LEUKAPHERESIS; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VACCINE PRODUCTION;

EID: 0029966638     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90071-9     Document Type: Article

References (15)

1. Ra Miller Dg Maloney R. Warnke R. Levy Treatment of B cell lymphoma with monoclonal anti-idiotype therapy N Engl J Med 306 1982 517 522
2. Tj Hamblin Ar Cattan Mj Glennie Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody Blood 69 1987 790 797
3. Aj George Sg Folkard Tj Hamblin Fk Stevenson Idiotypic vaccination as a treatment for B cell lymphoma J Immunol 141 1988 2168 2174
4. Fj Hsu Kl Kwak M. Campbell Clinical trials of idiotypic specific vaccine in B cell lymphomas Ann N Y Acad Sci 690 1993 385 387
5. Mh Tao R. Levy Idiotype/granulocyte-macrophage colony stimulating factor fusion protein as a vaccine for B cell lymphoma Nature 362 1993 755 758
6. Tt Chen Mh Tao R. Levy Idiotype-cytokine fusion proteins as cancer vaccines: relative efficiency of IL-2, IL-4, and granulocytemacrophage colony stimulating factor J Immunol 153 1994 4775 4787
7. Bj McCabe Kr Irvine Mi Nishimura Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumour cytolytic T lymphocyte responses Cancer Res 55 1995 1741 1747
8. Rm Steinman The dendritic cell system and its role in immunogenicity Annu Rev Immunol 9 1991 271 296
9. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony stimulating factor plus interleukin-4 and downregulated by tumour necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
10. M. Takamizawa F. Fagnoni Da Mehta A. Rivas Eg Engleman Cellular and molecular basis of human gamma delta T activation: role of accessory molecules in alloactivation J Clin Invest 95 1995 296 303
11. V. Flamand T. Sornasse K. Thielemans Murine dendritic cells pulsed in vitro with tumour antigen induce tumour resistance in vivo Eur J Immunol 42 1994 605 610
12. Fj Hsu C. Benike F. Fagnoni Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nature Med 2 1996 52 58
13. Re Hawkins D. Zhu M. Ovecka Idiotypic vaccination against human B-cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single chain Fv personal vaccines Blood 83 1994 3279 3288
14. M. Marchand F. Brasseur P. van der Bruggen P. Coulie T. Boon Perspectives for immunisation of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1 Dermatology 186 1993 278 280
15. Y. Kotera Jd Fontenot G. Pecher Rs Metzgar Oj Finn Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients Cancer Res 54 1994 2856 2860